BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 25056375)

  • 1. Evidence for molecular differences in prostate cancer between African American and Caucasian men.
    Khani F; Mosquera JM; Park K; Blattner M; O'Reilly C; MacDonald TY; Chen Z; Srivastava A; Tewari AK; Barbieri CE; Rubin MA; Robinson BD
    Clin Cancer Res; 2014 Sep; 20(18):4925-34. PubMed ID: 25056375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.
    Fontugne J; Cai PY; Alnajar H; Bhinder B; Park K; Ye H; Beg S; Sailer V; Siddiqui J; Blattner-Johnson M; Croyle JA; Noorzad Z; Calagua C; MacDonald TY; Axcrona U; Bogaard M; Axcrona K; Scherr DS; Sanda MG; Johannessen B; Chinnaiyan AM; Elemento O; Skotheim RI; Rubin MA; Barbieri CE; Mosquera JM
    JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35050902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SPOP mutations in prostate cancer across demographically diverse patient cohorts.
    Blattner M; Lee DJ; O'Reilly C; Park K; MacDonald TY; Khani F; Turner KR; Chiu YL; Wild PJ; Dolgalev I; Heguy A; Sboner A; Ramazangolu S; Hieronymus H; Sawyers C; Tewari AK; Moch H; Yoon GS; Known YC; Andrén O; Fall K; Demichelis F; Mosquera JM; Robinson BD; Barbieri CE; Rubin MA
    Neoplasia; 2014 Jan; 16(1):14-20. PubMed ID: 24563616
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Biomarker Signature That May Predict Aggressive Disease in African American Men With Prostate Cancer.
    Yamoah K; Johnson MH; Choeurng V; Faisal FA; Yousefi K; Haddad Z; Ross AE; Alshalafa M; Den R; Lal P; Feldman M; Dicker AP; Klein EA; Davicioni E; Rebbeck TR; Schaeffer EM
    J Clin Oncol; 2015 Sep; 33(25):2789-96. PubMed ID: 26195723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
    Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
    Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.
    Huang KC; Evans A; Donnelly B; Bismar TA
    Pathol Oncol Res; 2017 Apr; 23(2):399-407. PubMed ID: 27738792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular profiling of ETS and non-ETS aberrations in prostate cancer patients from northern India.
    Ateeq B; Kunju LP; Carskadon SL; Pandey SK; Singh G; Pradeep I; Tandon V; Singhai A; Goel A; Amit S; Agarwal A; Dinda AK; Seth A; Tsodikov A; Chinnaiyan AM; Palanisamy N
    Prostate; 2015 Jul; 75(10):1051-62. PubMed ID: 25809148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of 1577 primary prostate cancers reveals novel biological and clinicopathologic insights into molecular subtypes.
    Tomlins SA; Alshalalfa M; Davicioni E; Erho N; Yousefi K; Zhao S; Haddad Z; Den RB; Dicker AP; Trock BJ; DeMarzo AM; Ross AE; Schaeffer EM; Klein EA; Magi-Galluzzi C; Karnes RJ; Jenkins RB; Feng FY
    Eur Urol; 2015 Oct; 68(4):555-67. PubMed ID: 25964175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clonal evaluation of early onset prostate cancer by expression profiling of ERG, SPINK1, ETV1, and ETV4 on whole-mount radical prostatectomy tissue.
    Lu Z; Williamson SR; Carskadon S; Arachchige PD; Dhamdhere G; Schultz DS; Stricker H; Peabody JO; Jeong W; Chitale DA; Bismar TA; Rogers CG; Menon M; Gupta NS; Palanisamy N
    Prostate; 2020 Jan; 80(1):38-50. PubMed ID: 31584209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and Prognostic Significance of PTEN Loss in African-American and European-American Men Undergoing Radical Prostatectomy.
    Tosoian JJ; Almutairi F; Morais CL; Glavaris S; Hicks J; Sundi D; Humphreys E; Han M; De Marzo AM; Ross AE; Tomlins SA; Schaeffer EM; Trock BJ; Lotan TL
    Eur Urol; 2017 May; 71(5):697-700. PubMed ID: 27477529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular characterization of prostate cancer in Middle Eastern population highlights differences with Western populations with prognostic implication.
    Abdelsalam RA; Khalifeh I; Box A; Kalantarian M; Ghosh S; Abou-Ouf H; Lotfi T; Shahait M; Palanisamy N; Bismar TA
    J Cancer Res Clin Oncol; 2020 Jul; 146(7):1701-1709. PubMed ID: 32350606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions and relationships of PTEN, ERG, SPINK1 and AR in castration-resistant prostate cancer.
    Bismar TA; Yoshimoto M; Duan Q; Liu S; Sircar K; Squire JA
    Histopathology; 2012 Mar; 60(4):645-52. PubMed ID: 22260502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular alterations in prostate cancer and association with MRI features.
    Lee D; Fontugne J; Gumpeni N; Park K; MacDonald TY; Robinson BD; Sboner A; Rubin MA; Mosquera JM; Barbieri CE
    Prostate Cancer Prostatic Dis; 2017 Dec; 20(4):430-435. PubMed ID: 28762374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
    Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
    J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
    Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
    Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.
    Grupp K; Diebel F; Sirma H; Simon R; Breitmeyer K; Steurer S; Hube-Magg C; Prien K; Pham T; Weigand P; Michl U; Heinzer H; Kluth M; Minner S; Tsourlakis MC; Izbicki JR; Sauter G; Schlomm T; Wilczak W
    Prostate; 2013 Nov; 73(15):1690-8. PubMed ID: 23843146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in frequency of ERG oncoprotein expression between index tumors of Caucasian and African American patients with prostate cancer.
    Rosen P; Pfister D; Young D; Petrovics G; Chen Y; Cullen J; Böhm D; Perner S; Dobi A; McLeod DG; Sesterhenn IA; Srivastava S
    Urology; 2012 Oct; 80(4):749-53. PubMed ID: 22950997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Racial Variations in Prostate Cancer Molecular Subtypes and Androgen Receptor Signaling Reflect Anatomic Tumor Location.
    Faisal FA; Sundi D; Tosoian JJ; Choeurng V; Alshalalfa M; Ross AE; Klein E; Den R; Dicker A; Erho N; Davicioni E; Lotan TL; Schaeffer EM
    Eur Urol; 2016 Jul; 70(1):14-17. PubMed ID: 26443432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients.
    Magi-Galluzzi C; Tsusuki T; Elson P; Simmerman K; LaFargue C; Esgueva R; Klein E; Rubin MA; Zhou M
    Prostate; 2011 Apr; 71(5):489-97. PubMed ID: 20878952
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.